At a glance
- Glucagon is an FDA-approved drug, marketed as Glucagon, Baqsimi, Gvoke (first approval: May 8, 2015).
- PubMed lists 1,359 publications mentioning it, including 116 randomized controlled trials and 183 animal-only studies.
- ClinicalTrials.gov lists 1,528 registered studies testing it (374 active).
- FDA's adverse event system (FAERS) holds 5,243 reports mentioning it; 4,035 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| NDA012122 | GLUCAGON | Approved, discontinued | November 14, 1960 | LILLY |
| NDA020918 | GLUCAGEN | Approved, discontinued | June 22, 1998 | NOVO NORDISK |
| NDA020928 | GLUCAGON | Approved, discontinued | September 11, 1998 | LILLY |
| NDA201849 | GLUCAGON | Approved, marketed | May 8, 2015 | FRESENIUS KABI USA |
| NDA210134 | BAQSIMI | Approved, marketed | July 24, 2019 | AMPHASTAR PHARMS INC |
| NDA212097 | GVOKE HYPOPEN, GVOKE KIT, GVOKE PFS, GVOKE VIALDX | Approved, marketed | September 10, 2019 | XERIS |
| ANDA208086 | GLUCAGON | Approved, marketed | December 28, 2020 | AMPHASTAR PHARMS INC |
| ANDA204468 | GLUCAGON | Approved, marketed | December 12, 2024 | MYLAN LABS LTD |
| ANDA214457 | GLUCAGON | Approved, marketed | July 22, 2025 | LUPIN |
| ANDA218813 | GLUCAGON | Approved, marketed | September 15, 2025 | CIPLA |
| ANDA071022 | GLUCAGON | Approved, discontinued | — | QUAD PHARMS |
| ANDA071023 | GLUCAGON | Approved, discontinued | — | QUAD PHARMS |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Combined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse model.
- A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity.
- Mahvash disease: A novel case of apparent monoallelic disease and a novel cause of hypoglycaemia.
- IcoSema in Weight Management and Glycaemic Control: A Systematic Review and Meta-Analysis.
- Assessment of Preparedness for Medical Emergencies in Saudi Dental Colleges: A National Cross-Sectional Study.
- Closing the Gap to Bariatric Surgery: Predictors of Non-Progression in Patients with Obesity Class IV and V at a Community-Based Bariatric Center.
- The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Post-Anesthetic Pulmonary and Gastrointestinal Adverse Events: A Target Trial Emulation Using Multinational Database.
- Diabetes Care Knowledge-Practice Gap Among Primary Healthcare Nurses in Saudi Arabia: A Cross-Sectional Assessment of Competency and Training Needs.
- Adrenal hormones in the maintenance of glucose homeostasis during prolonged fasting in male glucagon-deficient mice.
- Efficacy and safety of HRS-7535, a novel oral small-molecule glucagon-like peptide-1 receptor agonist, in participants with type 2 diabetes mellitus inadequately controlled by metformin and sodium-glucose co-transporter 2 inhibitors: a multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase II trial.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 1,528
- Active
- 374
- With posted results
- 321
Conditions studied
Show 40 more studies
All 1,528 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 5,243
- Serious
- 4,035
- With death outcome
- 782
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
- Glucagon
- Glucagon
- Gvoke VialDx
- Baqsimi
- Glucagon
- Glucagon
- Glucagon 1555
- Glucagon
- Baqsimi
- GLUCAGON
- Glucagon
- Glucagon
- GLUCAGON
- Glucagon
- Glucagon
- Glucagon
- Metabolism Manager
- Weight Management Support
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.